Immunomedics posts positive data of its experimental cancer drug and Medicure meets primary endpoints in Phase II diabetic hypertension study.

0 Comments | M2 Presswire, September, 2005

M2 PRESSWIRE-22 September 2005-US Financial Network: Immunomedics posts positive data of its experimental cancer drug and Medicure meets primary endpoints in Phase II diabetic hypertension study(C)1994-2005 M2 COMMUNICATIONS LTD RDATE:22092005 City of Industry, CA - Biotechnology industry news provided by Financial News USA (OTC: FNWU) Immunomedics Inc.

(Nasdaq: IMMU) said Wednesday that a German study of its experimental cancer therapy showed that patients taking its drug after surgery lived twice as long as those receiving standard chemotherapy drugs or who went without treatment. The five-year study monitored 19 patients who had surgery to remove spreading cancer from their livers. About half of the group survived through to the end of the period....

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)